Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasm Metastasis 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Melanoma 2Lymphoproliferative Disorders 2Leukemia, Myeloid, Acute 2Glioma 2Brain Neoplasms 2Uveal Melanoma 1Thrombocytosis 1Sarcoma 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Noonan Syndrome 6 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Ipilimumab 17Nivolumab 15incomplete Freund's adjuvant 8Cyclophosphamide 7CTLA-4 Antigen 7pembrolizumab 6Ranibizumab 6sargramostim 5Radiosurgery 5Blood Specimen Collection 5tebentafusp 4Temozolomide 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4MART-1 Antigen 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4Bevacizumab 4fludarabine phosphate 3fludarabine 3aflibercept 3Thalidomide 3Sunitinib 3Specimen Handling 3MAGEA3 protein, human 3Interleukin-2 3130-nm albumin-bound paclitaxel 3relatlimab 2olaparib 2montanide ISA 51 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uveal Melanoma × entrectinib × Clear all
NCT04589832 2023-11-22

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Hoosier Cancer Research Network

Phase 1/2 Terminated
6 enrolled 9 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡